Azoles resistance reversal by oridonin in Candida albicans
Abstract Background Candida albicans (C. albicans) is a yeast causing hazardous fungal infections with high mortality, especially accompanied by resistance to azole drugs (fluconazole, itraconazole and voriconazole). To overcome the azoles resistance of C. albicans, we explored the Oridonin (ORI) with three azole drugs mainly focused on the synergistic activity. In this study, C. albicans strains were obtained from cancer patients, and the reversal of drug resistance of azole-resistant C. albicans was further studied. Methods The synergistic antifungal activities of ORI and azoles were measured by checkerboard microdilution and time-kill assays. The resistance reversal mechanisms, inhibition of drug efflux and induction of apoptosis, were investigated by flow cytometry after Annexin V-FITC/PI co-staining. The expression levels of efflux pump related genes CDR1 and CDR2 were quantitatively detected by qRT-PCR. Results The azole-resistant isolates identified by checkerboard microdilution method and time-kill curves. The efflux pump inhibition assay with ORI showed that the MIC of fluconazole (128-fold), itraconazole (64-fold) and voriconazole (250-fold) decreased significantly. The upregulation of genes coding for CDR1 and CDR2 were confirmed by qPCR with respect to the housekeeping gene ACT1 in the resistant strain. The sensitizing effect of ORI on fluconazole in the treatment of C. albicans also includes promoting apoptosis. We demonstrated that the combination of azoles with ORI exerted potent synergism and further displayed that ORI could promote the sensitization to azoles for azoles-resistant C. albicans. Conclusions We speculate that the resistance to azoles depends on the overexpression of efflux pump and its related genes CDR1 and CDR2, which reduces the accessibility of antifungal agents to C. albicans. The discovery that ORI can effectively inhibit drug efflux and promote apoptosis may provide new insights and therapeutic strategies for overcoming the increasing azole resistance in C. albicans infections.